LEXINGTON, Mass., June 20, 2018 /PRNewswire/ -- Aldeyra
Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology
company devoted to development of next-generation medicines to
improve the lives of patients with immune-mediated diseases, today
announced that it will host a Research Day to provide an update on
current early-stage research programs. The day will include
presentations from members of the management team focusing on
development plans for novel product candidates in systemic
inflammatory disease, retinal disease, and cancer.
Management presentations will begin at 9:00 a.m. Eastern Time on Tuesday, June 26, 2018,
at the offices of Dechert, LLP in New
York City.
A live webcast of the presentation and slide deck will be
available via the Company's Investor Relations website at
http://ir.aldeyra.com. Following the live webcast, an
archived version will be available on the website until
June 25, 2019.
About Aldeyra Therapeutics
Aldeyra
Therapeutics is developing next-generation medicines to improve the
lives of patients with immune-mediated diseases. Aldeyra's lead
product candidate, reproxalap, is a first-in-class treatment in
late-stage development for dry eye disease and other forms of
ocular inflammation. The company is also developing other product
candidates for autoimmune and metabolic diseases. None of Aldeyra's
product candidates have been approved for sale in the U.S. or
elsewhere.
Corporate Contact:
David McMullin
Aldeyra Therapeutics, Inc.
Tel: +1 781-761-4904 ext. 218
dmcmullin@aldeyra.com
Investor Contact:
Chris Brinzey
Westwicke Partners
Tel: 339-970-2843
Chris.brinzey@westwicke.com
Media Contact:
Cammy Duong
MacDougall Biomedical Communications
781-591-3443
cduong@macbiocom.com
View original
content:http://www.prnewswire.com/news-releases/aldeyra-therapeutics-announces-2018-research-day-300669225.html
SOURCE Aldeyra Therapeutics, Inc.